Luye Pharma
Luye Pharma Group Ltd., commonly referred to as Luye Pharma, is a prominent biopharmaceutical company headquartered in China (CN). Established in 1997, the company has made significant strides in the pharmaceutical industry, focusing on innovative drug development and manufacturing. With a strong presence in major operational regions including Asia, Europe, and North America, Luye Pharma is dedicated to addressing unmet medical needs across various therapeutic areas. The company’s core products encompass a range of advanced formulations, particularly in oncology, central nervous system disorders, and cardiovascular diseases. Luye Pharma is recognised for its unique drug delivery systems, which enhance the efficacy and patient compliance of its therapies. With a commitment to research and development, Luye Pharma has achieved notable milestones, positioning itself as a key player in the global biopharmaceutical market.
DitchCarbon Score
How does Luye Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Luye Pharma's score of 38 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Luye Pharma's reported carbon emissions
In 2024, Luye Pharma reported total carbon emissions of approximately 67,669,950 kg CO2e. This figure includes Scope 1 emissions of about 8,000,000 kg CO2e, derived from stationary combustion (7,963,990 kg CO2e), mobile combustion (57,764 kg CO2e), and fugitive emissions (1,944,840 kg CO2e). Additionally, Scope 2 emissions from purchased electricity and steam accounted for approximately 57,078,220 kg CO2e, with 40,480,190 kg CO2e from purchased electricity and 17,078,030 kg CO2e from purchased steam. Comparatively, in 2023, the company’s total emissions were about 76,201,350 kg CO2e, indicating a significant reduction in emissions year-on-year. The breakdown for 2023 shows Scope 1 emissions at approximately 8,283,500 kg CO2e and Scope 2 emissions at around 64,918,080 kg CO2e. Luye Pharma has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Luye Pharma Group Ltd. Overall, Luye Pharma's commitment to reducing its carbon footprint is evident through its decreasing emissions trend, although further details on specific reduction strategies or targets are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 9,105,040 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 42,156,830 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Luye Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
